CORRECTED VERSION*

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07J 41/00, 43/00, 41/00

A2

(11) International Publication Number: WO 99/33859

(43) International Publication Date: 8 July 1999 (08.07.99)

(21) International Application Number: PCT/US98/27406

(22) International Filing Date: 23 December 1998 (23.12.98)

(30) Priority Data:
08/998,877 24 December 1997 (24.12.97) US

(71) Applicant: SRI INTERNATIONAL [US/US]; 333 Ravenswood Avenue, Menlo Park, CA 94025 (US).

(72) Inventors: TANABE, Masato; 972 Moreno, Palo Alto, CA 94303 (US). PETERS, Richard, H.; 365 Springpark Circle, San Jose, CA 95136 (US). CHAO, Wan-Ru; 1510 Oriole Avenue, Sunnyvale, CA 94087 (US). JONG, Ling; 681 Endicott Drive, Sunnyvale, CA 94087 (US).


(74) Agents: REED, Dianne, E. et al.; Reed & Associates, 3282 Alpine Road, Portola Valley, CA 94028 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: NOVEL ANTI-ESTROGENIC STEROIDS, AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE



Effect of Compounds 85 and 92 on trabecular density in ovariectomized rats after treatment for 26 days.
#,##) P<0.05, 0.01 (vs OVX) *,**) P<P<0.05, 0.01 (vs Sham)

(57) Abstract

Novel anti-estrogenic compounds are provided which are useful to treat a variety of disorders, particularly estrogen-dependant disorders. Preferred compounds have 1,3,5-estratiene nucleus, and are substituted at the C-17 or C-11 position with a molecular moiety which renders the compounds effective to competitively block the binding of estrogen to its receptor. Particularly preferred compounds are 17-desoxy-1,3,5-estratienes. Therapeutic methods and pharmaceutical compositions are provided as well.